Accuray (ARAY) vs Intelligent Bio Solutions (INBS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Accuray is the larger company by market cap ($6.2 million vs $4.6 million), about 1.4 times the size, while Intelligent Bio Solutions is growing revenue faster (+38.1% vs -12.3%). Accuray converts more of its revenue into profit, with a net margin of -12.2% versus -294.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARAY | INBS |
|---|---|---|
| Share price | $2.08 | $1.39 |
| Market cap | $6.22M | $4.61M |
| 1-day change | -2.12% | -7.95% |
| YTD return | +153.05% | — |
| 1-year return | +97.62% | — |
| 5-year return | -59.47% | — |
| Forward P/E | — | 3.97 |
| EPS (TTM) | $-5.60 | $-6.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $401.95M | $4.22M |
| Revenue growth (YoY) | -12.34% | +38.09% |
| Net income (latest FY) | $-49.19M | $-12.43M |
| Gross margin | 27.73% | 48.63% |
| Operating margin | -6.58% | -299.11% |
| Net margin | -12.24% | -294.91% |
| 52-week high | $45.20 | $24.90 |
| 52-week low | $2.05 | $1.35 |
| Distance from 52-week high | -95.41% | -94.42% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +763.31% |
| Average volume | 201.35K | 129.01K |
| Shares outstanding | 3.00M | 3.32M |
| Employees | 809 | 59 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Accuray is more profitable, keeping -12.2 cents of every revenue dollar as net income versus -294.9 cents for Intelligent Bio Solutions.
- Intelligent Bio Solutions grew revenue faster in its latest fiscal year (+38.09% vs -12.34%).
About Accuray
ARAY stock →Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Health Care · Medical/Dental Instruments · 809 employees
About Intelligent Bio Solutions
INBS stock →Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform.
Health Care · Medical/Dental Instruments · 59 employees
ARAY vs INBS FAQ
Which is bigger, Accuray or Intelligent Bio Solutions?
Accuray (ARAY) is larger, with a market capitalization of $6.22M compared with $4.61M for Intelligent Bio Solutions (INBS).
Are Accuray and Intelligent Bio Solutions in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.